Levetiracetam Mabo

Levetiracetam, the active ingredient in Levetiracetam Mabo, is an anticonvulsant presented as an oral tablet for oral use. It is employed to control various seizure types in patients diagnosed with epilepsy and is indicated for both focal and generalized seizure disorders.

GNH USA supplies Levetiracetam Mabo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery, regulatory compliance, and quality assurance across European and global markets.

Levetiracetam is an antiepileptic drug used to manage seizure disorders by stabilizing neuronal firing.

- Partial seizures: Reduces frequency and severity of focal onset seizures. - Generalized tonic‑clonic seizures: Controls convulsive episodes in patients with generalized epilepsy. - Myoclonic seizures: Decreases sudden muscle jerks associated with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate cranial pain. - Irritability: mood changes or increased agitation. - Nausea: upset stomach, sometimes with vomiting.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood disorders: depression or suicidal thoughts. - Hematologic abnormalities: low blood cell counts. - Multiorgan hypersensitivity: liver or kidney dysfunction. - Stevens‑Johnson syndrome: severe skin blistering.

Before initiating levetiracetam therapy, consider the following precautions to ensure safe use.

- Renal impairment: adjust dose based on renal function. - Hepatic dysfunction: monitor liver enzymes periodically. - Psychiatric history: observe for mood changes or suicidal ideation. - Concomitant CNS depressants: assess additive sedation risk. - Pregnancy and lactation: evaluate risk‑benefit; limited data available. - Store at below 25°C: keep in original container, protect from moisture and light.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: may decrease therapeutic effect of levetiracetam. - Rifampin: induces metabolism, lowering drug exposure.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam concentrations. - Sedative agents (e.g., benzodiazepines): enhanced CNS depression. - Oral contraceptives: potential reduction in contraceptive efficacy.